about
Anti-retroviral effects of type I IFN subtypes in vivoImpact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cellsComparison of human B cell activation by TLR7 and TLR9 agonists.Patterns of oligonucleotide sequences in viral and host cell RNA identify mediators of the host innate immune systemWhy functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses.Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoExpression of the T cell receptor αβ on a CD123+ BDCA2+ HLA-DR+ subpopulation in head and neck squamous cell carcinoma.CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent mannerThe adjuvant activity of CpG DNA requires T-bet expression in dendritic cellsThe Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells.Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand.Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c MiceBasic concepts of immune response and defense development.The role of adjuvants in the development of mucosal vaccines.Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy.DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitisImmunostimulatory DNA as a vaccine adjuvant.Resident and "inflammatory" dendritic cells in human skin.Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes.Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Assessing the safety of adjuvanted vaccines.TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis.Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12.Cationic Nanohydrogel Particles for Therapeutic Oligonucleotide Delivery.Mesenteric lymph node cells from neonates present a prominent IL-12 response to CpG oligodeoxynucleotide via an IL-15 feedback loop of amplification.Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals.Translating Mouse Models.
P2860
Q28585391-DDBF6117-DE93-45F2-B384-4720420355E2Q33285471-7C713119-57B0-459D-A804-AA8BBCB430B3Q33354786-3C10553B-6D25-4A87-9230-4E23EAFB77B2Q33470303-F2D9C9CC-C752-49E0-A65F-233E870511A7Q33587443-5F0C0CFA-1E1D-43BC-88AE-4420A30DF97EQ33776347-1612F759-A1D5-4445-93C4-A0BDF530CC49Q33788621-4828AB00-AA1D-4304-9BAC-77FAA1153A02Q33802831-E2A58582-43CE-457B-824B-731C7640092DQ33902560-5A25A947-FAA8-48B3-8536-B4D0D31E9A74Q33948105-EC7553E2-A19A-439F-BD38-82478FDF8A73Q34124090-B2A7DB1F-48A8-417D-AB93-5B9362B21566Q34208310-D1FDEFA2-F497-48ED-9C9B-124AD0EA2E81Q34291783-6D41894D-745B-48C0-AC49-FE920ABCE140Q35676749-A94D589E-DFBA-4C47-BEE5-80A29B6C6FFDQ35689200-1E4465D8-EC1C-405B-839D-2C2A2E1160E6Q36161895-1C98643A-B6DD-4E6C-9F94-4EB7B9CB094EQ36194084-A2DE3EF8-E969-43D9-997F-614AFD7F2D49Q36316635-A7762387-76BD-4D8D-89D4-038FEA994414Q36445502-7B99E303-CE48-432C-9F14-C8AA142F4DFAQ36497063-F8BBEC90-9F54-45A3-B8AE-53C3EBAD293FQ36968274-91F721B5-364C-4827-B7B7-7176DE5D183FQ37237339-B322DD03-CB97-403C-97AC-D7B66662751FQ37309247-9DEDB444-D8BA-4ABB-A7C9-94F9396F3C81Q37328524-AC1773CE-DBF6-4712-B6FF-270E3F78B81AQ37447389-0C9FAEBC-38D4-4541-8D6C-855636DD1EACQ37671216-AB9634F1-A6EB-4BF2-8F36-B0F8F3AAF5D6Q37906961-4FD6C796-5FA0-4E4F-BA6D-8D0A7AD7CB36Q38267788-FCE5FB76-664F-47B4-B7DC-B3BDB198C623Q38342241-1D949914-E2A1-48A0-AC56-9F7B27998DBAQ39366778-8835A0DF-7F24-40CC-8175-BA2E68186B75Q42140847-91FA2319-BDDD-4186-9E97-B37403B27644Q45090402-6DC158A0-10C2-4993-B3B6-D081755C3579Q46463280-FF44A36C-13E5-4430-817B-4EFC0C03AEE4
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Plasmacytoid dendritic cells: the key to CpG.
@ast
Plasmacytoid dendritic cells: the key to CpG.
@en
Plasmacytoid dendritic cells: the key to CpG.
@nl
type
label
Plasmacytoid dendritic cells: the key to CpG.
@ast
Plasmacytoid dendritic cells: the key to CpG.
@en
Plasmacytoid dendritic cells: the key to CpG.
@nl
prefLabel
Plasmacytoid dendritic cells: the key to CpG.
@ast
Plasmacytoid dendritic cells: the key to CpG.
@en
Plasmacytoid dendritic cells: the key to CpG.
@nl
P2093
P1433
P1476
Plasmacytoid dendritic cells: the key to CpG.
@en
P2093
Evelyn Tuma
Gunther Hartmann
Simon Rothenfusser
Stefan Endres
P304
P356
10.1016/S0198-8859(02)00749-8
P577
2002-12-01T00:00:00Z